Gastric Cancer This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

The combination of gene hyperamplification and PD-L1 expression as a biomarker for the clinical benefit of tislelizumab in gastric/gastroesophageal junction adenocarcinoma
ConclusionsIn GEA, PD-L1 positivity, IFNγ-related gene signature and TMB-high status were positively associated with tislelizumab clinical benefit, whereas HA was associated with worse clinical outcomes. Combining PD-L1 positivity and HA − may help identify patients more likely to benefit from PD-1 blockade. (Source: Gastric Cancer)
Source: Gastric Cancer - July 2, 2022 Category: Gastroenterology Source Type: research

Usefulness of an S-1 dosage formula: an exploratory analysis of randomized clinical trial (JCOG1001)
ConclusionsDose optimization using an S-1 dosage formula can potentially reduce grade ≥ 3 adverse events for overdosed patients. (Source: Gastric Cancer)
Source: Gastric Cancer - June 29, 2022 Category: Gastroenterology Source Type: research